Otsuka Pharmaceuticals and Click Therapeutics have received FDA clearance for their smartphone-based prescription digital therapeutic, Rejoyn, for major depressive disorder. The six-week remote treatment program combines cognitive emotional training and therapeutic exercises to improve brain connections involved in depression. Expected to launch in 2024, Rejoyn is designed as a neuromodulatory mechanism to enhance brain function. The partnership between Otsuka and Click has shown commitment to exploring digital therapeutics interventions, as seen in previous collaborations and partnerships with other companies. Click Therapeutics has also made significant financial advancements and acquisitions in the digital therapeutics space.
Source link
Otsuka, Click Therapeutics get FDA clearance for prescription digital therapeutic
